@Article{Kocurek2016,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
volume="20",
number="4",
year="2016",
title="Primary mediastinal B-cell lymphoma – metabolic and anatomical features in 18FDG-PET/CT and response to therapy",
abstract=" Aim of the study : Determining the role of PET/CT imaging in the evaluation of treatment efficacy in primary mediastinal B-cell lymphoma (PMBCL).    Material and methods : Retrospective analysis of seven PMBCL patients, treated at the University Hospital in Krakow, with interim PET/CT after the third course of chemo-immunotherapy. The analysis was based on the calculation of exact tumour volume and metabolic activity, compared with initial values (directly after diagnosis).     Results:   Patients (five females, two males, average age 26.2 years, range 18–40 years), in clinical stage IIBX at diagnosis, were treated with eight cycles of R-CHOP-14 regimen, with radiotherapy consolidation (7/7) and central nervous system prophylaxis (6/7).  The observed decrease in tumour volume between the initial staging and the interim PET ranged 72–89%. The mean ∆SUV max  reduction between initial (when available) and interim PET was 87% (range 84–89%). In 3/7 cases in the interim PET/CT, the uptake of the tumour was higher than the liver (Deauville Criteria score 4–5), and in 4/7 it was lower than the liver but higher than mediastinal blood pool structures (score 3 according to Deauville Criteria). After a median follow-up of 58 months – OS and EFS is 100%.    Conclusions:   The excellent clinical outcome in the study group corresponds with very good metabolic and volumetric response in the interim PET. The ∆SUV max  seems to be easier in implementation and has a more significant impact than other measurements.",
author="Kocurek, Anna
and Małkowski, Bogdan
and Giza, Agnieszka
and Jurczak, Wojciech",
pages="297--301",
doi="10.5114/wo.2016.61849",
url="http://dx.doi.org/10.5114/wo.2016.61849"
}